secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001104659-25-044372
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax amends Takeda COVID vaccine pact; gets $19.5M upfront, tiered royalties
-------------------------------------------------------------------------------

- Upfront payment $19.5M from Takeda; $5M creditable against royalties for Takeda FY2024.
- Annual $2M service fee plus $8M milestone if Takeda gets marketing approval; $5M of milestone creditable.
- Profit share replaced with tiered royalty on net sales in mid-to-high teens, effective April 1, 2024.
- Takeda may develop a different vaccine strain but must procure it from Novavax.
- Parties also entered release agreement settling all claims related to original 2021 pact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925044372/0001104659-25-044372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925044372/tm2513960d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-044372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer